Communiqués Protara Therapeutics, Inc.

Actions

TARA

US74365U1079

Temps réel estimé Cboe BZX Autres places de cotation 19:33:50 16/07/2024			Varia. 5j.	Varia. 1 janv.
2,48 ^USD	+4,20 %		+16,90 %	+32,79 %

02/05	Protara Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
05/04	Protara Therapeutics, Inc. annonce un alignement avec la FDA sur la voie de l'enregistrement pour le chlorure de choline IV chez les patients dépendant de la nutrition parentérale	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	24/06	AQ
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit	21/05	AQ
Protara Therapeutics: Q1 Earnings Snapshot	02/05	AQ
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update	02/05	AQ
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing	05/04	AQ
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	05/04	AQ
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC	05/04	AQ
Protara Therapeutics: Q4 Earnings Snapshot	13/03	AQ
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	13/03	AQ
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	28/02	AQ
Protara Therapeutics to Participate in Upcoming Investor Conferences	31/01	AQ
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology	30/11	AQ
Protara Therapeutics: Q3 Earnings Snapshot	03/11	AQ
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update	03/11	AQ
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations	23/10/23	AQ
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09/10/23	AQ
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ	20/09/23	AQ
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	05/09/23	AQ
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update	03/08/23	AQ
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ	15/05/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Protara Therapeutics, Inc.

Actions

TARA

US74365U1079

Communiqués

Filtres